Answers are grounded in this paper and cite their sources.
BACKGROUND & AIMS: Targeted therapies for biliary tract cancers (BTC) are approved in second line. We investigated response to first-line platinum-based palliative systemic anti-cancer treatment in patients with the most common druggable alterations to determine the optimal positioning of targeted therapies in the treatment algorithm. METHODS: Patients treated at the Beatson West of Scotland centralized BTC clinic who underwent genomic profiling were retrospectively selected; those with the most common actionable alterations who received platinum-based treatment were included in clinical analyses. Observations were supported by tracking IDH1 mutations with digital droplet PCR on longitudinal cell free DNA samples. RESULTS: 39.7% of patients had druggable alterations; HER2 overexpression/amplification and IDH1 R132 mutations were the most common ones. Compared to patients with HER2-positive tumors (N=11), patients with IDH1 R132 mutations (N=6) had longer median time to best response (5.99 vs 2.5 months; HR 0.28; 95%CI, 0.09-0.91; p=0.0033), and median time to progression (TTP) (17.2 vs 5.6 months; HR 0.266; 95%CI, 0.0955-0.741; p=0.0075). Compared to a cohort of patients without either alterations, those with IDH1-mutated BTC had longer median overall survival (OS) (HR 0.30; 95%CI, 0.14-0.67; p=0.0229); those with HER2-positive BTC showed a worse median TTP (HR 1.97; 95%CI, 0.85-4.58; p=0.0408) and a trend towards worse median OS (HR 1.38; 95%CI, 0.61-3.13; p=0.3884). IDH1 VAF decreased during first line, regardless of response; prolonged benefit from ivosidenib in second line was observed when VAF was <1 at start of targeted treatment. CONCLUSIONS: These preliminary data might indicate that targeted therapies should be introduced in first line with different strategies depending on molecular alterations, with access to platinum-based palliative systemic anti-cancer treatment being important for patients with IDH1-mutated BTC. IMPACT AND IMPLICATIONS: We conducted an analysis to determine whether patients with biliary tract cancer harboring the most common actionable alterations (i.e. IDH1 R132 mutations and HER2 overexpression or amplification) had different patterns of response to first-line platinum-based chemo(immuno)therapy. The goal was to determine whether the introduction of targeted therapies in first line should have a tailored approach based on the alteration detected. In our cohort, patients with IDH1 R132 mutations had durable benefit from platinum-based chemotherapy, while those with HER2-positive tumors had a short-lived benefit from it. While our results are speculative in nature due to the small sample size, they may inform future approaches to the implementation of targeted agents in an earlier setting, with appropriate design of large clinical trials.
No takes yet. Share an insight, caveat, or question.
Tesini et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: